江苏新鑫隆医药科技股份有限公司（苏州市鑫隆化工有限公司）

Jiangsu Xinxinlong Pharmaceutical Technology Co., Ltd. and Hubei Huaxing New Materials Technology Co., Ltd. are subsidiaries of Suzhou Xinlong Chemical Co., Ltd. Established in 1998 and located in the picturesque Jiangnan water town of Suzhou, Xinlong Chemical currently operates two production bases. It is a comprehensive, modern manufacturing enterprise focused on the research, development, production, sales, and operation of pharmaceutical intermediates and new materials, with contract custom processing as a supplementary business. Its products are applied in industries such as pharmaceuticals, veterinary drugs, pesticides, dyes, and new materials. The company holds self-operated import and export rights and is recognized as an AAA credit enterprise.

       Jiangsu Xinxinlong Pharmaceutical Technology Co., Ltd. was established in 2006 and is located in the Lin'gang Industrial Park of Guanyun County, Jiangsu Province, a provincial-level chemical industrial park covering nearly 150 acres.

Hubei Huaxing New Materials Technology Co., Ltd. was established in 2019 and is situated in the Jintongling Industrial Park of Zhuxi County, Hubei Province, also a provincial-level chemical industrial park spanning nearly 360 acres.

       The company consistently prioritizes customer needs, establishing a stable and reliable quality assurance system and a strong reputation. It has fully implemented digital automated production and currently employs over 300 people, with nearly 70% holding college degrees or higher. These employees, hailing from renowned institutions across the country, play crucial roles in the company's research, production, and management. The company is now building a two-tier R&D center and a multifunctional incubation workshop. It has formed industrial partnerships with several universities, actively enriching its product line, and is steadfastly introducing doctoral teams to lay a solid foundation for the future establishment of a doctoral workstation.

       Moving forward, the company will advocate for a low-carbon economy, integrate its resources, optimize its product structure, and accelerate industrial upgrading. It aims to become a leading domestic enterprise with strong international competitiveness and innovation capabilities in the near future. The company remains committed to its social responsibilities, striving tirelessly for the well-being of its employees, the healthy development of the national pharmaceutical industry, and the domestic substitution of new materials. At the same time, we firmly believe that, seizing the historical opportunities of "Made in China 2025," the company will continue to achieve new leaps and breakthroughs.